Abstract
Second-line (2L) treatment options for advanced renal cell carcinoma (aRCC) include the tyrosine kinase inhibitors (TKI) cabozantinib and axitinib. We characterized real-world (RW) use of cabozantinib (most recently approved TKI) and axitinib (most commonly used 2L TKI) for aRCC in England.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
